Observational multicenter Italian study on vulvar cancer adjuvant radiotherapy (OLDLADY 1.2): a cooperation among AIRO Gyn, MITO and MaNGO groups.
Adjuvant radiotherapy
Outcomes
Toxicity
Vulvar cancer
Journal
La Radiologia medica
ISSN: 1826-6983
Titre abrégé: Radiol Med
Pays: Italy
ID NLM: 0177625
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
09
05
2022
accepted:
28
07
2022
pubmed:
11
9
2022
medline:
26
10
2022
entrez:
10
9
2022
Statut:
ppublish
Résumé
Adjuvant radiotherapy (aRT) has been shown to reduce the risk of local relapse in vulvar cancer (VC). In this multicentre study (OLDLADY-1.2), several Institutions have combined their retrospective data on VC patients to produce a real-world dataset aimed at collecting data on efficacy and safety of aRT. The primary study end-point was the 2-year-local control, secondary end-points were the 2-year-metastasis free-survival, the 2-year-overall survival and the rate and severity of acute and late toxicities. Participating centres were required to fill data sets including age, stage, tumor diameter, type of surgery, margin status, depth of invasion, histology, grading as well technical/dosimetric details of radiotherapy. Data about response, local and regional recurrence, acute and late toxicities, follow-up and outcome measures were also collected. One hundred eighty-one patients with invasive VC from 9 Institutions were retrospectively identified. The majority of patients were stage III (63%), grade 2 (62.4%) squamous carcinoma (97.2%). Positive nodes were observed in 117 patients (64.6%), moreover tumor diameter > 4 cm, positive/close margins and depth of invasion deeper than 5 mm were found in 59.1%, 38.6%, 58% of patients, respectively. Sixty-one patients (33.7%) received adjuvant chemoradiation, and 120 (66.3%) received radiotherapy alone. aRT was started 3 months after surgery in 50.8% of patients. Prescribed volumes and doses heterogeneity was recorded according to margin status and nodal disease. Overall, 42.5% locoregional recurrences were recorded. With a median follow-up of 27 months (range 1-179), the 2-year actuarial local control rate, metastasis free and overall survival were 68.7%, 84.5%, and 67.5%, respectively. In term of safety, aRT leads to a prevalence of acute skin toxicity with a low incidence of severe toxicities. In the context of aRT for VC the present study reports a broad spectrum of approaches which would deserve greater standardization in terms of doses, volumes and drugs used.
Sections du résumé
BACKGROUND
BACKGROUND
Adjuvant radiotherapy (aRT) has been shown to reduce the risk of local relapse in vulvar cancer (VC). In this multicentre study (OLDLADY-1.2), several Institutions have combined their retrospective data on VC patients to produce a real-world dataset aimed at collecting data on efficacy and safety of aRT.
METHODS
METHODS
The primary study end-point was the 2-year-local control, secondary end-points were the 2-year-metastasis free-survival, the 2-year-overall survival and the rate and severity of acute and late toxicities. Participating centres were required to fill data sets including age, stage, tumor diameter, type of surgery, margin status, depth of invasion, histology, grading as well technical/dosimetric details of radiotherapy. Data about response, local and regional recurrence, acute and late toxicities, follow-up and outcome measures were also collected.
RESULTS
RESULTS
One hundred eighty-one patients with invasive VC from 9 Institutions were retrospectively identified. The majority of patients were stage III (63%), grade 2 (62.4%) squamous carcinoma (97.2%). Positive nodes were observed in 117 patients (64.6%), moreover tumor diameter > 4 cm, positive/close margins and depth of invasion deeper than 5 mm were found in 59.1%, 38.6%, 58% of patients, respectively. Sixty-one patients (33.7%) received adjuvant chemoradiation, and 120 (66.3%) received radiotherapy alone. aRT was started 3 months after surgery in 50.8% of patients. Prescribed volumes and doses heterogeneity was recorded according to margin status and nodal disease. Overall, 42.5% locoregional recurrences were recorded. With a median follow-up of 27 months (range 1-179), the 2-year actuarial local control rate, metastasis free and overall survival were 68.7%, 84.5%, and 67.5%, respectively. In term of safety, aRT leads to a prevalence of acute skin toxicity with a low incidence of severe toxicities.
CONCLUSIONS
CONCLUSIONS
In the context of aRT for VC the present study reports a broad spectrum of approaches which would deserve greater standardization in terms of doses, volumes and drugs used.
Identifiants
pubmed: 36088437
doi: 10.1007/s11547-022-01538-w
pii: 10.1007/s11547-022-01538-w
doi:
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1292-1302Informations de copyright
© 2022. Italian Society of Medical Radiology.
Références
Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65:5–29
doi: 10.3322/caac.21254
Eifel PJ, Berek JS, Markman MA (2011) Cancer of the cervix, vagina, and vulva. In: DeVita VT Jr, Lawrence TS, Rosenberg SA (eds) DeVita, Hellman, and Rosenberg’s cancer: principles and practices of oncology. Williams & Wilkins, Philadelphia
Morley GW (1976) Infiltrative carcinoma of the vulva: results of surgical treatment. Am J Obstet Gynecol 124:874–888. https://doi.org/10.1016/s0002-9378(16)33392-0
doi: 10.1016/s0002-9378(16)33392-0
pubmed: 943950
Podratz KC, Symmonds RE, Taylor WF et al (1983) Carcinoma of the vulva: analysis of treatment and survival. Obstet Gynecol 61:63–74
pubmed: 6823350
Andersen BL, Hacker NF (1983) Psychosexual adjustment after vulvar surgery. Obst Gynecol 62:457–462
Te Grootenhuis NC, van der Zee AG, van Doorn HC et al (2016) Sentinel nodes in vulvar cancer: long-term follow-up of the Groningen international study on sentinel nodes in vulvar cancer (GROINSS-v) I. Gynecol Oncol 140:8–14. https://doi.org/10.1016/j.ygyno.2015.09.077
doi: 10.1016/j.ygyno.2015.09.077
Heaps JM, Fu YS, Montz FJ et al (1990) Surgical-pathologic variables predictive of local recurrence in squamous cell carcinoma of the vulva. Gynecol Oncol 38:309–314. https://doi.org/10.1016/0090-8258(90)90064-r
doi: 10.1016/0090-8258(90)90064-r
pubmed: 2227541
Tagliaferri L, Garganese G, D’Aviero A et al (2020) Multidisciplinary personalized approach in the management of vulvar cancer - the Vul. Can Team experience. Int J Gynecol Cancer 30:932–938. https://doi.org/10.1136/ijgc-2020-001465
doi: 10.1136/ijgc-2020-001465
pubmed: 32474446
Tagliaferri L, Lancellotta V, Casà C et al (2021) The radiotherapy role in the multidisciplinary management of locally advanced vulvar cancer: a multidisciplinary vulcan team review. Cancers (Basel) 13:5747. https://doi.org/10.3390/cancers13225747
doi: 10.3390/cancers13225747
Homesley HD, Bundy BN, Sedlis A et al (1991) Assessment of current international federation of gynecology and obstetrics staging of vulvar carcinoma relative to prognostic factors for survival (a Gynecologic Oncology Group study). Am J Obstet Gynecol 164:997–1003. https://doi.org/10.1016/0002-9378(91)90573-a
doi: 10.1016/0002-9378(91)90573-a
pubmed: 2014852
Federico F, Forte S, Ardighieri L et al (2019) Multivariate analysis of prognostic factors in primary squamous cell vulvar cancer: the role of perineural invasion in recurrence and survival. Eur J Surg Oncol 45:2115–2119. https://doi.org/10.1016/j.ejso.2019.07.029
doi: 10.1016/j.ejso.2019.07.029
Miljanović-Špika I, Drežnjak Madunić M, Topolovec Z et al (2021) Prognostic factors for vulvar cancer. Acta Clin Croat 60:25–32. https://doi.org/10.20471/acc.2021.60.01.04
doi: 10.20471/acc.2021.60.01.04
pubmed: 34588718
pmcid: 8305353
Chapman BV, Gill BS, Viswanathan AN et al (2017) Adjuvant radiation therapy for margin-positive vulvar squamous cell carcinoma: defining the ideal dose-response using the National Cancer Database. Int J Radiat Oncol Biol Phys 97:107–117. https://doi.org/10.1016/j.ijrobp.2016.09.023
doi: 10.1016/j.ijrobp.2016.09.023
pubmed: 27843030
Kunos C, Simpkins F, Gibbons H et al (2009) Radiation therapy compared with pelvic node resection for node-positive vulvar cancer: a randomized controlled trial. Obstet Gynecol 114:537–546. https://doi.org/10.1097/AOG.0b013e3181b12f99
doi: 10.1097/AOG.0b013e3181b12f99
pubmed: 19701032
Swanick CW, Eifel PJ, Huo J et al (2017) Challenges to delivery and effectiveness of adjuvant radiation therapy in elderly patients with node-positive vulvar cancer. Gynecol Oncol 146:87–93. https://doi.org/10.1016/j.ygyno.2017.05.004
doi: 10.1016/j.ygyno.2017.05.004
pubmed: 28506563
pmcid: 5896777
Parthasarathy A, Cheung MK, Osann K et al (2006) The benefit of adjuvant radiation therapy in single-node-positive squamous cell vulvar carcinoma. Gynecol Oncol 103:1095–1099. https://doi.org/10.1016/j.ygyno.2006.06.030
doi: 10.1016/j.ygyno.2006.06.030
pubmed: 16889821
Mahner S, Jueckstock J, Hilpert F et al (2015) AGO-CaRE-1 Investigators. Adjuvant therapy in lymph node-positive vulvar cancer: the AGO-CaRE-1 study. J Natl Cancer Inst 107:426. https://doi.org/10.1093/jnci/dju426
doi: 10.1093/jnci/dju426
Gill BS, Bernard ME, Lin JF et al (2015) Impact of adjuvant chemotherapy with radiation for node-positive vulvar cancer: a National Cancer Database (NCDB) analysis. Gynecol Oncol 137:365–372. https://doi.org/10.1016/j.ygyno.2015.03.056
doi: 10.1016/j.ygyno.2015.03.056
pubmed: 25868965
Ignatov T, Eggemann H, Burger E et al (2016) Adjuvant radiotherapy for vulvar cancer with close or positive surgical margins. J Cancer Res Clin Oncol 142:489–495. https://doi.org/10.1007/s00432-015-2060-9
doi: 10.1007/s00432-015-2060-9
pubmed: 26498775
Gaffney DK, King B, Viswanathan AN et al (2016) Consensus recommendations for radiation therapy contouring and treatment of vulvar carcinoma. Int J Radiat Oncol Biol Phys 95:1191–1200. https://doi.org/10.1016/j.ijrobp.2016.02.043
doi: 10.1016/j.ijrobp.2016.02.043
pubmed: 27130794
pmcid: 5189987
Grégoire V, Guckenberger M, Haustermans K et al (2020) Image guidance in radiation therapy for better cure of cancer. Mol Oncol 14:1470–1491. https://doi.org/10.1002/1878-0261.12751
doi: 10.1002/1878-0261.12751
pubmed: 32536001
pmcid: 7332209
Moore DH, Thomas GM, Montana GS et al (1998) Preoperative chemoradiation for advanced vulvar cancer: a phase II study of the Gynecologic Oncology Group. Int J Radiat Oncol Biol Phys 42:79–85. https://doi.org/10.1016/s0360-3016(98)00193-x
doi: 10.1016/s0360-3016(98)00193-x
pubmed: 9747823
Aragona AM, Cuneo NA, Soderini AH et al (2014) An analysis of reported independent prognostic factors for survival in squamous cell carcinoma of the vulva: Is tumor size significance being underrated? Gynecol Oncol 132:643–648. https://doi.org/10.1016/j.ygyno.2013.12.022
doi: 10.1016/j.ygyno.2013.12.022
pubmed: 24418199
Greer BE, Koh WJ (2016) New NCCN guidelines for vulvar cancer. J Natl Compr Canc Netw 14:656–658
doi: 10.6004/jnccn.2016.0184
Dudley S, Viswanathan A (2019) Margins in vulvar cancer: challenges to classical clinicopathologic vulvar recurrence risk factors. Gynecol Oncol 154:253–254. https://doi.org/10.1016/j.ygyno.2019.07.007
doi: 10.1016/j.ygyno.2019.07.007
pubmed: 31331493
Te Grootenhuis NC, Pouwer AW, de Bock GH et al (2019) Margin status revisited in vulvar squamous cell carcinoma. Gynecol Oncol 154:266–275. https://doi.org/10.1016/j.ygyno.2019.05.010
doi: 10.1016/j.ygyno.2019.05.010
Common Terminology Criteria for Adverse Events (CTCAE) Version 5. Published: November 27. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute
Micheletti L, Preti M, Zola P et al (1998) A proposed glossary of terminology related to the surgical treatment of vulvar carcinoma. Cancer 83:1369–1375
doi: 10.1002/(SICI)1097-0142(19981001)83:7<1369::AID-CNCR14>3.0.CO;2-2
Jolly S, Soni P, Gaffney DK et al (2015) ACR appropriateness criteria adjuvant therapy in vulvar cancer. Oncology 29:867–875
pubmed: 26568534
Khullar K, Patrich T, Jabbour SK, Hathout L (2022) Adjuvant radiation in early stage vulvar cancer: a review of indications and optimal dose. Appl Radiat Oncol 11:14–20
pubmed: 35445143
pmcid: 9017798
Mahantshetty U, Naga P, Engineer R et al (2017) Clinical outcome of high-dose-rate interstitial brachytherapy in vulvar cancer: a single institutional experience. Brachytherapy 16:153–160
doi: 10.1016/j.brachy.2016.10.003
Han SC, Kim DH, Higgins SA, Carcangiu ML, Kacinski BM (2000) Chemoradiation as primary or adjuvant treatment for locally advanced carcinoma of the vulva. Int J Radiat Oncol Biol Phys 47:1235–1244
doi: 10.1016/S0360-3016(00)00569-1
Zapardiel I, Iacoponi S, Coronado PJ et al (2020) Prognostic factors in patients with vulvar cancer: the VULCAN study. Int J Gynecol Cancer 30:1285–1291. https://doi.org/10.1136/ijgc-2019-000526
doi: 10.1136/ijgc-2019-000526
pubmed: 32571891
Gill BS, Bernard ME, Lin JF et al (2015) Impact of adjuvant chemotherapy with radiation for node-positive vulvar cancer: a National Cancer Data Base (NCDB) analysis. Gynecol Oncol 137:365–372
doi: 10.1016/j.ygyno.2015.03.056
Lee CW, Dupré S, Marlborough F et al (2022) Postoperative radiotherapy delay in head and neck cancer patients undergoing major resection and free flap reconstruction. J Plast Reconstr Aesthet Surg. https://doi.org/10.1016/j.bjps.2022.02.038
doi: 10.1016/j.bjps.2022.02.038
pubmed: 36167710
Burger MP, Hollema H, Emanuels AG et al (1995) The importance of the groin node status for the survival of T1 and T2 vulval carcinoma patients. Gynecol Oncol 57:327–334. https://doi.org/10.1006/gyno.1995.1151
doi: 10.1006/gyno.1995.1151
pubmed: 7774836
Raspagliesi F, Hanozet F, Ditto A et al (2006) Clinical and pathological prognostic factors in squamous cell carcinoma of the vulva. Gynecol Oncol 102:333–337. https://doi.org/10.1016/j.ygyno.2005.12.027
doi: 10.1016/j.ygyno.2005.12.027
pubmed: 16466657
Rhodes CA, Cummins C, Shafi MI (1998) The management of squamous cell vulval cancer: a population based retrospective study of 411 cases. Br J Obstet Gynaecol 105:200–205. https://doi.org/10.1111/j.1471-0528.1998.tb10053.x
doi: 10.1111/j.1471-0528.1998.tb10053.x
pubmed: 9501787
Sun X, Zhang Y, Sun J, Feng S, Yan M, Cheng H (2012) The comparative study of former and latest FIGO staging of vulvar cancer. Minerva Chir 67:187–195
pubmed: 22487921
Tagliaferri L, Budrukkar A, Lenkowicz J et al (2018) ENT COBRA ONTOLOGY: the covariates classification system proposed by the Head & Neck and Skin GEC-ESTRO Working Group for interdisciplinary standardized data collection in head and neck patient cohorts treated with interventional radiotherapy (brachytherapy). J Contemp Brachyther 10:260–266. https://doi.org/10.5114/jcb.2018.76982
doi: 10.5114/jcb.2018.76982
Tagliaferri L, Gobitti C, Colloca GF et al (2018) A new standardized data collection system for interdisciplinary thyroid cancer management: thyroid COBRA. Eur J Intern Med 53:73–78. https://doi.org/10.1016/j.ejim.2018.02.012
doi: 10.1016/j.ejim.2018.02.012
pubmed: 29477755
Tagliaferri L, Pagliara MM, Masciocchi C et al (2017) Nomogram for predicting radiation maculopathy in patients treated with Ruthenium-106 plaque brachytherapy for uveal melanoma. J Contemp Brachyther 9:540–547. https://doi.org/10.5114/jcb.2017.71795
doi: 10.5114/jcb.2017.71795
Meldolesi E, van Soest J, Alitto AR et al (2014) VATE: VAlidation of high TEchnology based on large database analysis by learning machine. Colorectal Cancer 5:435–450. https://doi.org/10.2217/crc.14.34
doi: 10.2217/crc.14.34
Lancellotta V, Guinot JL, Fionda B et al (2020) SKIN-COBRA (Consortium for Brachytherapy data Analysis) ontology: the first step towards interdisciplinary standardized data collection for personalized oncology in skin cancer. J Contemp Brachytherapy 12:105–110. https://doi.org/10.5114/jcb.2020.94579
doi: 10.5114/jcb.2020.94579
pubmed: 32395133
pmcid: 7207239